Kymera Therapeutics (KYMR) News Today $56.29 -0.63 (-1.11%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$56.30 +0.01 (+0.02%) As of 04:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KYMR Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Keudell Morrison Wealth Management Invests $334,000 in Kymera Therapeutics, Inc. $KYMROctober 5, 2025 | marketbeat.comBrokerages Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Price Target at $59.95October 5, 2025 | americanbankingnews.comOppenheimer Maintains Kymera Therapeutics (KYMR) Outperform RecommendationOctober 2, 2025 | msn.comKymera Therapeutics (NASDAQ:KYMR) Sets New 52-Week High on Analyst UpgradeOctober 2, 2025 | americanbankingnews.comKymera Therapeutics price target raised to $68 from $53 at TruistOctober 1, 2025 | msn.comTruist Securities Maintains Kymera Therapeutics (KYMR) Buy RecommendationOctober 1, 2025 | msn.comTruist Financial Boosts Kymera Therapeutics (NASDAQ:KYMR) Price Target to $68.00October 1, 2025 | americanbankingnews.comKymera Therapeutics (NASDAQ:KYMR) Hits New 52-Week High Following Analyst UpgradeOctober 1, 2025 | marketbeat.comTruist Financial Raises Kymera Therapeutics (NASDAQ:KYMR) Price Target to $68.00September 30, 2025 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Recommendation of "Buy" from AnalystsSeptember 30, 2025 | marketbeat.comKymera Therapeutics (KYMR): Revisiting Valuation After Recent Share Price MomentumSeptember 29, 2025 | finance.yahoo.comKymera Therapeutics (NASDAQ:KYMR) Reaches New 12-Month High - Time to Buy?September 25, 2025 | marketbeat.comStocks To Watch: Kymera Therapeutics Sees RS Rating Jump To 83September 25, 2025 | msn.comVoya Investment Management LLC Lowers Stock Holdings in Kymera Therapeutics, Inc. $KYMRSeptember 24, 2025 | marketbeat.comHC Wainwright Has Positive Estimate for KYMR FY2029 EarningsSeptember 22, 2025 | marketbeat.comHC Wainwright Increases Kymera Therapeutics (NASDAQ:KYMR) Price Target to $70.00September 19, 2025 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Rating Increased to Strong-Buy at BarclaysSeptember 19, 2025 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) CFO Sells $3,961,000.00 in StockSeptember 18, 2025 | marketbeat.comKymera Therapeutics price target raised to $70 from $60 at H.C. WainwrightSeptember 18, 2025 | msn.comKymera Therapeutics (NASDAQ:KYMR) Coverage Initiated by Analysts at BarclaysSeptember 18, 2025 | marketbeat.comInsider Selling: Kymera Therapeutics (NASDAQ:KYMR) CFO Sells 79,220 Shares of StockSeptember 18, 2025 | insidertrades.comKymera Therapeutics, Inc. $KYMR Shares Bought by Rhumbline AdvisersSeptember 18, 2025 | marketbeat.comKymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and ...September 17, 2025 | finance.yahoo.comBarclays Initiates Coverage of Kymera Therapeutics (KYMR) with Overweight RecommendationSeptember 17, 2025 | msn.comNello Mainolfi Sells 30,000 Shares of Kymera Therapeutics (NASDAQ:KYMR) StockSeptember 17, 2025 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Coverage Initiated at Royal Bank Of CanadaSeptember 17, 2025 | marketbeat.comKymera Therapeutics Presents Promising Phase 1 Results for KT-621 at Major European ConferencesSeptember 17, 2025 | quiverquant.comQKymera Therapeutics (NASDAQ:KYMR) CEO Sells $1,470,000.00 in StockSeptember 17, 2025 | insidertrades.comRBC Capital Initiates Coverage of Kymera Therapeutics (KYMR) with Outperform RecommendationSeptember 17, 2025 | msn.comKymera Therapeutics initiated with an Overweight at BarclaysSeptember 16, 2025 | msn.comBreaking Down Kymera Therapeutics: 4 Analysts Share Their ViewsSeptember 16, 2025 | benzinga.comKymera is a new Outperform at RBC Capital Markets on lead assetSeptember 16, 2025 | msn.comKymera Therapeutics initiated with an Outperform at RBC CapitalSeptember 16, 2025 | msn.comTop 3 Biotech Stocks to Watch According to BofA Global ResearchSeptember 15, 2025 | finance.yahoo.comWoodline Partners LP Has $14.38 Million Stock Position in Kymera Therapeutics, Inc. $KYMRSeptember 13, 2025 | marketbeat.comKymera Therapeutics, Inc. $KYMR Shares Bought by Siren L.L.C.September 13, 2025 | marketbeat.comKymera Therapeutics, Inc. (KYMR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 9, 2025 | seekingalpha.comKymera Therapeutics, Inc. $KYMR Shares Sold by Cinctive Capital Management LPSeptember 8, 2025 | marketbeat.comWhy Kymera (KYMR) Could Be One of Biotech’s Most Interesting Growth Stories?September 7, 2025 | msn.comNorthern Trust Corp Lowers Stock Position in Kymera Therapeutics, Inc. $KYMRSeptember 7, 2025 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Recommendation of "Buy" from AnalystsSeptember 7, 2025 | marketbeat.comKymera Therapeutics Announces New Chief Legal OfficerSeptember 6, 2025 | theglobeandmail.comEventide Asset Management LLC Grows Position in Kymera Therapeutics, Inc. $KYMRSeptember 6, 2025 | marketbeat.comCheckpoint Capital L.P. Has $3.74 Million Stock Position in Kymera Therapeutics, Inc. $KYMRSeptember 6, 2025 | marketbeat.com10,059 Shares in Kymera Therapeutics, Inc. $KYMR Acquired by Walleye Capital LLCSeptember 6, 2025 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Stock Price Up 5.7% - Here's WhySeptember 5, 2025 | marketbeat.comRedmile Group LLC Lowers Holdings in Kymera Therapeutics, Inc. $KYMRSeptember 4, 2025 | marketbeat.comKymera Therapeutics, Inc. (KYMR) Presents At Citi's 2025 Biopharma Back To School Conference TranscriptSeptember 3, 2025 | seekingalpha.comKymera Therapeutics appoints Adams as Chief Legal Officer, Corporate SecretarySeptember 3, 2025 | msn.comKymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate SecretarySeptember 3, 2025 | globenewswire.com Get Kymera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KYMR Media Mentions By Week KYMR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KYMR News Sentiment▼0.470.63▲Average Medical News Sentiment KYMR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KYMR Articles This Week▼37▲KYMR Articles Average Week Get the Latest News and Ratings for KYMR and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Kymera Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies SMMT News Today RDY News Today ASND News Today VTRS News Today ROIV News Today QGEN News Today ELAN News Today BBIO News Today MRNA News Today VRNA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KYMR) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kymera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kymera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
